In Vitro–In Vivo Correlation in Dosage Form Development: Case Studies

  • Shoufeng Li
  • Alan E. Royce
  • Abu T. M. Serajuddin

In vitro and in vivo correlation (IVIVC) refers to a predictive relationship of the in vitro properties of drug substances or dosage forms with their in vivo performance. For orally administered drug products, it is usually a correlation between the extent or rate of dissolution of a dosage form and its pharmacokinetic parameters, such as rate, duration, and extent of drug absorption. The physicochemical properties of dosage forms influence their in vivo performance in many different ways (Li et al., 2005). Through the establishment of a definitive relationship between certain physicochemical properties of a dosage form with the in vivo appearance of its active component, one can establish in vitro testing criteria which will predict, its in vivo performance.


Dosage Form Dissolution Method Life Cycle Management Metoprolol Tartrate Tartrate Salt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agoram, B., Woltosz, W.S., and Bolger, M.B. (2001). Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50:S41-S67.CrossRefPubMedGoogle Scholar
  2. Amidon, G.L., Lennernas, H., Shah, V.P., and Crison, J.R. (1995). Theoretical basis for a biopharmaceutical drug classification: correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3):413-420.CrossRefPubMedGoogle Scholar
  3. Center for Drug Evaluation and Research (CDER) (1997). Guidance for Industry: Extended release oral dosage forms: development, evaluation, and application of in-vitro/in-vivo correlation. Rockville, MD. US Department of Health and Human Services, Food and Drug Administration.Google Scholar
  4. Center for Drug Evaluation and Research (CDER) (2000). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration.Google Scholar
  5. Chiou, W.L., Ma, C., Chung, S.M., Wu, T.C., Jeong, H.Y. (2000). Similarity in the linear non-linear oral absorption of drugs between human and rat. Int. J. Clin. Pharmacol. Ther. 38:532-539.PubMedGoogle Scholar
  6. Corrigan, O.I., Devlin, Y., and Butler, J. (2003). Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Int. J. Pharm. 254(2):147-154.CrossRefPubMedGoogle Scholar
  7. Curatolo, W. (1998). Physical chemical properties of oral drug candidates in the discovery and exploratory setting. Pharm. Sci. Tech. Today 1:387.CrossRefGoogle Scholar
  8. Dannenfelser, R.-M., He, H., Joshi, Y., Bateman, S., and Serajuddin, A.T.M. (2004). Development of clinical dosage forms for a poorly water soluble drug I: application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J. Pharm. Sci. 93:1165-1175.CrossRefPubMedGoogle Scholar
  9. Dunne, A., O’Hara, T., and DeVane, J. (1997). Level A in vivo-in vitro correlation: nonlin-ear models and statistical methodology. J. Pharm. Sci. 86(11):1245-1249.CrossRefPubMedGoogle Scholar
  10. Frick, A., M öller, H., and Wirbitzky, E. (1998). Biopharmaceutical characterization of oral controlled/modified-release drug products. In vitro/in vivo correlation of roxatidine. Eur. J. Pharm. Biopharm. 46:313-319.CrossRefPubMedGoogle Scholar
  11. Horter, D. and Dressman, J.B. (1997). Influence of physicochemical properties on dissolu-tion of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 25:3-14.CrossRefGoogle Scholar
  12. Huang, Y.-B., Tsai, Y.-H., Yang, W.-C., Chang, J.-S., Wu, P.-C., and Takayama, K. (2004). Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur. J. Pharm. Biopharm. 58:607-614.CrossRefPubMedGoogle Scholar
  13. Johnson, K.C. and Swindell, A.C. (1996). Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 13:1795-1798.CrossRefPubMedGoogle Scholar
  14. Langenbucher, F. (2002). Handling of computational in vitro/in vivo correlation problems by Microsoft Excel II. Principles and some general Algorithms. Eur. J. Pharm. Bio-pharm. 53:1-7.CrossRefGoogle Scholar
  15. Li, S., He, H., Parthiban, L.J., Yin, H., and Serajuddin, A.T.M. (2005). IV-IVC considerations in the development of immediate-release oral dosage form. J. Pharm. Sci. 94 (7):1397-1417.CrossRefGoogle Scholar
  16. Li, S., Mueller-Zsigmondy, M., and Yin, H. (2007). The role of IVIVC in product develop-ment and life cycle management in pharmaceutical product development: In vitro-in vivo correlation. In: Chilukuri, D., Sunkara, G., Young, D. (eds.), Pharmaceutical Product Development (Drugs and the Pharmaceutical Sciences), Marcel Dekker Inc., New York.Google Scholar
  17. Mahayni, H., Rekhi, G.S., and Uppoor, R.S. (2000). Evaluation of external predictability of an in vitro-in vivo correlation for an extended-release formulation containing Metoprolol Tartrate. J. Pharm. Sci. 89(10):1354-1361.CrossRefPubMedGoogle Scholar
  18. Polli, J.E., Crison, J.R., and Amidon, G.L. (1996). Novel approach to the analysis of in vitro-in vivo relationships. J. Pharm. Sci., 85:753-760.CrossRefPubMedGoogle Scholar
  19. Polli, J.E., Rekhi, G.S., Augsburger, L.L., and Shah, V.P. (1997). Methods to compare disso-lution profiles and a rationale for wide dissolution specifications for Metoprolol Tartrate tablets. J. Pharm. Sci. 86(6):690-700.CrossRefPubMedGoogle Scholar
  20. Pudipeddi, M., Serajuddin, A.T.M., and Mufson, D. (2006). Integrated drug product devel-opment - from lead candidate selection to life-cycle management. In: Smith, C.G. and O’Donnell, J.T. (eds.), The Process of New Drug Discovery and Development, 2nd ed. Informa Healthcare USA, Inc., New York, pp. 15-51.Google Scholar
  21. Qiu, Y., Garren, J., Samara, E., Cao, G., Abraham, C., Cheskin, H.S., and Engh, K.R. (2003). Once-a-day controlled-release dosage form of Divalproex Sodium II: develop-ment of a predictive in vitro drug release method. J. Pharm. Sci. 92(11):2317-2325.CrossRefPubMedGoogle Scholar
  22. Takka, S., Sakr, A., and Goldberg, A. (2003). Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J. Control. Release 88:147-157.CrossRefPubMedGoogle Scholar
  23. Turner, S., Federici, C., Hite, M., and Fassihi, R. (2004). Formulation development and human in vitro-in vivo correlation for a novel, monolithic controlled-release matrix sys-tem of high load and highly water-soluble drug niacin. Drug Dev. Ind. Pharm. 30(8):797-807.Google Scholar
  24. United States Pharmacopeial Convention, Inc. (1988). In vitro-in vivo correlation for extended release oral dosage forms. Pharmacopeial Forum Stimuli Article 4160-4161.Google Scholar
  25. Venkatesh, S. and Lipper, R.A. (2000). Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89(2):145-154.CrossRefPubMedGoogle Scholar
  26. Yu, L.X., Crison, J.R., and Amidon, G.L. (1996a). Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 140:111-118.CrossRefGoogle Scholar
  27. Yu, L.X., Lipka, E., Crison, J.R., and Amidon, G.L. (1996b). Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev. 19:359-376.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Shoufeng Li
    • 1
  • Alan E. Royce
    • 1
  • Abu T. M. Serajuddin
    • 1
  1. 1.Novartis Pharmaceuticals CorporationEast HanoverUSA

Personalised recommendations